Search Results
Oct 23, 2025, 17:00 ET ARIS MINING ANNOUNCES Q3 2025 EARNINGS RELEASE DATE
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Oct 23, 2025, 16:05 ET Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Ratio [HR] 0.479; 95% CI: 0.33, 0.68); P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic
More news about: Inhibrx Biosciences, Inc.
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
extramedullary disease and the patient with pPCL achieved sCR and remained in remission at last follow-up. The median progression-free survival (PFS) was 18.2 months, with 12-month PFS and overall survival (OS) rates of 82.1% and 93.3%, respectively. Safety: Cytokine
More news about: IASO Bio
Oct 21, 2025, 10:00 ET FP Alpha announces First-of-Its-Kind NextGen Tax Insights now available, assisting financial advisors in their tax planning advice to clients
"This level of AI-driven personalization is the 'wow factor' that's been missing from traditional tax planning," added Robert S. Keebler, CPA/PFS, MST, AEP, CGMA and partner with Keebler & Associates, LLP. "By moving beyond static insights to dynamic, scenario-based projections, FP
More news about: FP Alpha
Oct 21, 2025, 09:20 ET Gold Hits $4,300+ Creating Opportunity Across the Mining Sector
dilution to our capital structure," said Alan Carter, President and CEO of Cabral Gold Inc. "The financial metrics included within the recent PFS study make for a compelling opportunity, with a capex cost of US$37.7M, a post tax IRR of 78%, an NPV of US$74M and a payback of just 10 months, at a
More news about: USA News Group
Oct 21, 2025, 08:23 ET Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
KIT-driven tumors with translational biomarkers of target engagement (KIT knock-down, tryptase/MRK signaling) and early efficacy readouts (ORR, DCR, PFS signals). NEW YORK,
More news about: Hoth Therapeutics, Inc.
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm
More news about: Leap Therapeutics, Inc.
Oct 20, 2025, 06:30 ET IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
safety and efficacy profile of darovasertib; (iii) the ongoing Phase 3 registrational trial (OptimUM-10) of darovasertib; (iv) the reporting of topline PFS data from the Phase2/3 (OptimUM-02) trial of darovasertib in combination with crizotinib by the end of 2025 to Q1'26; and (v) the potential U.S. accelerated
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 06:00 ET IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
months in published meta-analysis of metastatic uveal melanoma in the first-line setting Median progression free survival (PFS) of 7.0 months Confirmed overall response rate (ORR) by RECIST 1.1 of 34%, median duration of response (mDOR) of 9 months
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
platinum-based doublet chemotherapy, sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in both PFS and OS. Consistent PFS and OS benefits were observed across all prespecified subgroups, including prior EGFR-TKI therapy, presence of liver or brain metastases,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 20, 2025, 04:30 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
expression (IHC 2+ >20%), the 2.4 mg/kg dose cohort observed 1 CR, 11 PRs and 15 SDs, resulting in 40% ORR (12/30) and 90% DCR (27/30). The median PFS was 6.97 months and the 12-month OS rate was 66.2%. In the 1.8 mg/kg dose cohort, there were 1 CR, 9 PRs, and 11 SDs, giving a 40% ORR (10/25)
More news about: Antengene Corporation Limited
Oct 20, 2025, 02:44 ET ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
the study are PFS and OS, and the secondary endpoints include objective response rate (ORR), disease control rate (DCR), and safety, etc. Results as of March 31, 2025, showed: Regarding PFS, the median PFS in the disitamab
More news about: RemeGen Co., Ltd
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
Median PFS was significantly longer in trastuzumab botidotin than in T-DM1 (11.1 months vs 4.4 months; HR: 0.39, 95% CI, 0.30-0.51, p<0.0001). PFS benefit with trastuzumab botidotin was consistently observed regardless of prior
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 22:01 ET Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
date July 06, 2025, the median follow-up is 18.9 months. the median Progression-Free Survival (PFS) was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group. Sac-TMT significantly improved PFS over chemotherapy with 51% lower risk of disease progression or death (hazard ratio (HR) 0.49;
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 11:37 ET HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
regimen. Among patients with liver metastases, the PFS HR was 0.53; among those without liver metastases, the PFS HR was 0.64. For patients with ≥3 baseline metastatic sites, the PFS HR was 0.46, and for those with <3 baseline metastatic sites, the PFS HR was 0.64.
More news about: Akeso, Inc.
Oct 19, 2025, 10:30 ET VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
86% (19 of 22 patients achieved a partial response or stable disease). Median Progression-Free Survival (PFS) of 40 weeks, which is more than double the 15-week benchmark for standard-of-care salvage chemotherapy. Study
More news about: Vivace Therapeutics, Inc.
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
0.43; 95% CI 0.22 to 0.83). Furthermore, median progression-free survival (PFS) was 8.38 months with iza-bren compared to 4.34 months for chemotherapy (hazard ratio of 0.44; 95% confidence interval 0.32-0.62). The ORR and PFS benefits were consistent across all subgroup analysis. At the time of this
More news about: SystImmune, Inc.
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
at the data cut-off date January 22, 2025, the median PFS was significantly longer in sac-TMT than in ICC (8.3 vs. 4.1 months; HR, 0.35; 95% CI, 0.26-0.48; P<0.0001). Clinical benefit was seen in sac-TMT independent of HER2 expression (HR for PFS in HER2-zero: 0.39, 95% CI, 0.26-0.57; in HER2-low: 0.31,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
papillomavirus integration site mapping in advanced cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot.Second progression-free survival (PFS2) and subsequent treatment in patients (pts) with folate receptor alpha (FR⍺)-positive platinum-resistant ovarian cancer (PROC) treated with mirvetuximab
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
data cut-off, median values for duration of response (DoR) and progression-free survival (PFS) were not yet mature, with 47% of patients remaining on treatment and encouraging 6-month rates for DoR of 80% and PFS of 79%. Data presented at ESMO demonstrated a manageable safety profile
More news about: Boehringer Ingelheim
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
endpoints include objective response rate (ORR) by RECIST 1.1 criteria, duration of response (DoR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OR) and PK analysis. About EGFRmt NSCLC
More news about: SystImmune, Inc.
Oct 17, 2025, 05:42 ET Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) as assessed by the blinded independent central review (BICR) compared with T-DM1; the beneficial trend for overall survival (OS) of trastuzumab botidotin
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 16, 2025, 11:44 ET KENTRO PARTNERS WITH THE PFS TEAM ON THE VA INTEGRATED HEALTHCARE TRANSFORMATION 2.0 CONTRACT
MCLEAN, Va., Oct. 16, 2025 /PRNewswire/ -- Kentro is proud to partner with Prometheus Federal Services (PFS) on the Department of Veterans Affairs (VA) Integrated Healthcare Transformation 2.0 (IHT 2.0) contract. The 10-year, $14 billion multiple-award IDIQ
More news about: Kentro
Oct 16, 2025, 08:00 ET TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line
More news about: Johnson & Johnson
Oct 14, 2025, 17:31 ET Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
2024, reported that the STELLAR Phase III trial demonstrated a clinically meaningful improvement in Overall Survival (OS) and Progression-Free Survival (PFS) for patients with Grade 3 IDH-mutant astrocytoma who had progressed after radiation and adjuvant temozolomide, compared to lomustine alone. Since that
More news about: DelveInsight Business Research, LLP